



# Poor Birth Outcomes in Malaria in Pregnancy: Recent Insights Into Mechanisms and Prevention Approaches

Caroline L. L. Chua<sup>1</sup>, Wina Hasang<sup>2</sup>, Stephen J. Rogerson<sup>2\*</sup> and Andrew Teo<sup>2,3\*</sup>

<sup>1</sup> School of Biosciences, Taylor's University, Subang Jaya, Malaysia, <sup>2</sup> Department of Medicine at Royal Melbourne Hospital, Peter Doherty Institute, University of Melbourne, Melbourne, VIC, Australia, <sup>3</sup> Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore

## OPEN ACCESS

### Edited by:

Danielle Ilona Staniscic,  
Griffith University, Australia

### Reviewed by:

Prasanna Jagannathan,  
Stanford University, United States  
Stephanie Yanow,  
University of Alberta, Canada

### \*Correspondence:

Stephen J. Rogerson  
sroger@unimelb.edu.au  
Andrew Teo  
andrewcc.teo@ntu.edu.sg

### Specialty section:

This article was submitted to  
Microbial Immunology,  
a section of the journal  
Frontiers in Immunology

**Received:** 26 October 2020

**Accepted:** 23 February 2021

**Published:** 15 March 2021

### Citation:

Chua CLL, Hasang W, Rogerson SJ  
and Teo A (2021) Poor Birth  
Outcomes in Malaria in Pregnancy:  
Recent Insights Into Mechanisms and  
Prevention Approaches.  
Front. Immunol. 12:621382.  
doi: 10.3389/fimmu.2021.621382

Pregnant women in malaria-endemic regions are susceptible to malaria in pregnancy, which has adverse consequences on birth outcomes, including having small for gestational age and preterm babies. These babies are likely to have low birthweights, which predisposes to infant mortality and lifelong morbidities. During malaria in pregnancy, *Plasmodium falciparum*-infected erythrocytes express a unique variant surface antigen, VAR2CSA, that mediates sequestration in the placenta. This process may initiate a range of host responses that contribute to placental inflammation and dysregulated placental development, which affects placental vasculogenesis, angiogenesis and nutrient transport. Collectively, these result in the impairment of placental functions, affecting fetal development. In this review, we provide an overview of malaria in pregnancy and the different pathological pathways leading to malaria in pregnancy-associated low birthweight. We also discuss current prevention and management strategies for malaria in pregnancy, and some potential therapeutic interventions that may improve birth outcomes. Lastly, we outline some priorities for future research that could bring us one step closer to reducing this health burden.

**Keywords:** low birthweight, preterm birth, small for gestational age, malaria, pregnancy, VAR2CSA

## INTRODUCTION

Global efforts to combat malaria have resulted in declining malaria transmission in many regions over the last decade. Unfortunately, young children and pregnant women remain vulnerable, especially in areas with sustained transmission. Malaria, a disease caused by the *Plasmodium* spp. parasite, can result in severe morbidity and mortality. Worldwide, infection with *Plasmodium falciparum* contributes to the highest burden, and it will be the main focus of this review (1). Despite childhood exposure that leads to acquisition of immunity against malaria, first time pregnant mothers or primigravidas are again susceptible to the disease due to a combination of host and parasitic factors (2, 3). Malaria in pregnancy (MiP) results in placental infection, termed placental malaria (PM), which predisposes to placental injury and insufficiency. Placental insufficiency refers to poor placental function and is commonly observed in PM. It is also hypothesized to be a leading cause of low birthweight (LBW). A baby with LBW is defined as a live born who is <2,500 g regardless of gestational age (4). LBW deliveries can be due to preterm birth (live birth < 37 gestational weeks) or small for gestational age (SGA) (birthweight < 10th percentile for its

gestational age). Of note, the precise mechanisms behind MiP-associated preterm birth and SGA remains unclear. *P. falciparum* infection can cause inflammation and potentially disrupt the fine immunological balance required to maintain pregnancy to term (5–7). On the other hand, SGA is often linked to placental insufficiency and there is also substantial evidence to suggest dysregulated placental development in mothers with MiP (8, 9). Interestingly, preterm birth does not commonly co-exist with SGA, further highlighting the complexity of MiP-associated birth outcomes (10).

LBW is an important indicator of infant mortality. MiP is estimated to cause approximately 900,000 LBW deliveries annually, with an estimated 100,000 MiP-related infant deaths (1, 11). Apart from high mortality risk, there is also increased morbidity in the surviving LBW infants, who are at elevated risk of poor cognitive and social development (12). LBW due to fetal growth restriction, the cause of SGA, is linked to increased incidence of adult diseases including type 2 diabetes and cardiovascular diseases (13). Hence, the prevention of MiP-associated LBW remains a priority in research. In this review, we discuss recent findings on the causes of LBW in *P. falciparum*-MiP and the different pathological pathways such as SGA and preterm birth in contributing to MiP-associated LBW. We also highlight existing gaps in our knowledge on the pathogenesis of LBW in MiP. Lastly, we review current interventions and provide suggestions for future work that allows us to better understand and manage MiP.

## MALARIA IN PREGNANCY: AN OVERVIEW OF PATHOGENESIS AND IMMUNITY


Malaria in pregnancy threatens the well-being of the mother and her developing fetus, and an infected mother is likely to be an important reservoir of *Plasmodium* infection. One prominent feature of *P. falciparum*-infected erythrocytes (IEs) is their ability to adhere to endothelial and placental receptors. The latter allows them to sequester in the placenta, leading to placental infection and inflammation. Histological sections of *P. falciparum*-infected placentas reveal the presence of IEs, particularly at the surface of the syncytiotrophoblast, which is the main site of exchange for nutrient, waste and other metabolites between maternal and fetal circulations. Within the placental intervillous spaces, which are occupied by maternal blood, increased infiltrates of phagocytic cells with substantial amounts of ingested parasites can be observed; this is known as intervillitis (14, 15). The binding phenotype of IEs during pregnancy is mediated by their expression of variant surface antigens (VSA). Placental-binding parasites express VAR2CSA, a major VSA that is mainly expressed during pregnancy, and they bind specifically to the placental receptor known as chondroitin sulfate A (CSA) (16–19). Therefore, prior to pregnancy, antibodies against placental-binding IEs are uncommon, predisposing primigravidas to the adverse effects of PM (2, 20). In subsequent pregnancies, the protective anti-VAR2CSA antibodies can be naturally acquired in a gravidity-dependent manner and have been demonstrated to be effective against MiP and its consequences, thus preventing LBW

(21). However, the specific antigenic targets and mechanisms of protection remain unclear. A recent systematic review showed that antibodies against different placental-binding antigens including VAR2CSA were associated with increased risk of PM and its consequences, suggesting that they may be markers of infection instead of correlates of protection (22). Nonetheless, it is likely that antibodies that are protective can inhibit binding of IEs to the placenta and/or facilitate clearance through opsonising phagocytosis, thus prevent placental inflammation and the subsequent adverse effects on fetal growth (Figure 1), and defining the characteristics of potentially protective antibodies remains a priority.

## CAUSES OF MiP-ASSOCIATED LBW

### The Link Between MiP, Dysregulated Placental Development and Small for Gestational Age Babies

Small for gestational age is commonly caused by fetal growth restriction. This condition significantly increases the risk of LBW, stillbirth, infant mortality and morbidity, and the risk of being diagnosed with chronic diseases in adulthood (13). Interestingly, SGA infants were two times more likely to experience *Plasmodium*-infection and clinical malaria by the age of 6 months, after adjusting for mosquito exposure (23). A recent study from an area of low malaria transmission reported several factors that were associated with increased odds of SGA during *P. falciparum*-related MiP, including symptomatic malaria and infection after 12–16 weeks' gestation (24). In addition, the risk of SGA was reported to increase by 1.13 times for every episode of infection during pregnancy (24). In contrast, in areas of high malaria transmission and particularly when pregnant women received anti-malarials in the form of intermittent preventive treatment in pregnancy (IPTp), there was no association between number of malaria episodes and SGA, suggesting that the timing of MiP may contribute to increased risk of SGA (25, 26). Indeed, placental pigment deposition (past-chronic infection) was associated with increased risk of SGA but not LBW or preterm birth, suggesting early chronic infection (usually outside of IPTp coverage) may drive SGA and not preterm labor (25, 27). Alterations in the downstream pathways of MiP such as growth factors and their regulators may further contribute to SGA. Recently, reduced plasma concentrations of placental growth factor in mid-pregnancy were associated with SGA and may indicate early placental insufficiency (9). MiP is known to be associated with reduced expression and bioavailability of placental growth factor, with the latter occurring through increased expression of their soluble inhibitor, soluble fms-like tyrosine kinase-1 (sFlt-1) (26, 28, 29). In addition, MiP leads to increased levels of asymmetric dimethylarginine, which is a competitive inhibitor of nitric oxide synthase (29). When nitric oxide synthase is inhibited, nitric oxide production is similarly affected, resulting in increased sFlt-1 levels and reduced levels of vascular endothelial growth factor (VEGF) family of proteins (30). This subsequently leads to



dysregulated placental vasculogenesis and angiogenesis that may affect placental functions, contributing to SGA.

## The Link Between MiP, Inflammation and Preterm Babies

MiP is also associated with preterm birth, where these babies are usually born small and have increased risk of mortality due to complications such as brain hemorrhage, sepsis, acute respiratory illnesses and perinatal asphyxia (31). Surviving infants may develop life-long morbidities such as learning disabilities, which become obvious when the infant reaches school age (32). *Plasmodium* infection in both early and late pregnancies has been associated with preterm deliveries. A study from Malawi showed that earlier infection (before 24 weeks gestation) was associated with a higher risk of preterm delivery (26). In a Cameroon study, pregnant women who experienced MiP during the third trimester were four times more likely to have preterm deliveries (7). Similarly, in areas with low malaria transmission such as Southeast Asia, *P. falciparum* infection during late pregnancy was also associated with preterm delivery (24).

Studies on populations in malarious areas have identified several factors that significantly increase the risk of preterm birth, including PM, systemic inflammation (particularly CXCL9 and IL-1 $\beta$ ), primigravidity, long-term iron supplementation and

severe anemia (33–35). A recent systematic review found that maternal anemia in the first trimester, but not other trimesters, was associated with increased risk of preterm birth (36). Of note, the risk of MiP is highest during the first trimester, however, how severe maternal anemia contributes to preterm deliveries remains unclear. Interestingly, vertical parasite transmission, though uncommon, was also reported to contribute to preterm and LBW deliveries; this may partly be attributed to placental inflammation as higher complement activity was reported in cord blood infection (37, 38).

Several inflammatory mediators within the maternal peripheral circulation have also been associated with preterm delivery, but more investigations are required to understand whether they serve as biomarkers or play a pathological role. One of these markers is the soluble tumor necrosis factor receptor 2, which was found at increased levels in HIV positive women with MiP. Women who had elevated levels of this receptor throughout pregnancy also had preterm deliveries (6). Another study reported that in Papua New Guinean women who received one dose of IPTp with sulfadoxine-pyrimethamine (SP) and chloroquine, maternal serum levels of the acute phase protein  $\alpha$ 1-acid glycoprotein (AGP), an inflammatory marker, at delivery were positively correlated with several birth parameters including LBW, preterm and SGA deliveries (9). In

the same study, women with two or more doses of IPTp with SP and azithromycin (SPAZ) were observed to have reduced levels of AGP at delivery, suggesting that SPAZ may reduce inflammation thus preventing deleterious pregnancy outcomes (9). The levels of AGP were previously shown to be increased in *P. falciparum*-infected children and adults with uncomplicated malaria illness (39, 40), while the role of AGP in MiP, especially in higher transmission areas, requires further investigation. Our understanding of the pathways leading to preterm birth in MiP is still rather limited, although placental inflammation is likely to be a main contributing factor. During the initiation of labor, a pro-inflammatory environment is generated through the activation of maternal immune cells and placental stromal cells, which subsequently produce high levels of pro-inflammatory cytokines, prostaglandins and matrix-degrading enzymes. These are associated with the triggering of uterine contraction, cervical ripening and membrane rupture, signaling the beginning of the birthing process. In MiP, particularly PM with intervillitis, the massive leukocyte infiltrates may trigger an inflammatory environment similar to the one observed in labor, leading to the premature initiation of parturition. Various cytokines that are implicated in the induction of preterm birth such as IL-1 $\beta$ , IL-6, macrophage migration inhibitory factor and CXCL1 have also been found at elevated levels during MiP (33, 41). Recently, in a murine model of MiP, dysregulated expression of placental ATP-binding cassette transporters was associated with preterm labor (42). Further studies are required to determine if a similar mechanism operates in the human disease.

## POTENTIAL PATHWAYS LEADING TO MIP-ASSOCIATED LBW

### Effects of MiP on Placental Development

The placenta is an important organ that acts as an interface between the mother and her fetus. Successful placental development requires a fine immunological balance to be achieved between maternal, placental and fetal immunity. PM can alter nitric oxide bioavailability, and it may lead to host inflammatory responses. Either of these processes may result in poor placental development, leading to placental insufficiency when the placenta is unable to fully support the growth of the developing baby (26, 29).

The first trimester is associated with the highest risk of *Plasmodium*-infection especially in primigravid women (43, 44). Critically, the timing of infection appears to determine the risks and severity of adverse birth outcomes. For MiP, early exposure (<15 gestational weeks) was associated with reduced volume of placental transport villi and smaller surface areas for diffusion across the villi (45). Other abnormalities such as impaired development of placental vascular space, excessive syncytial knotting (aggregation of syncytiotrophoblast nuclei), increased fibrinoid necrosis areas and thickening of syncytiotrophoblast basal membrane have also been observed (46–48). The timing of infection that resulted in such placental pathologies, however, is unknown. Ultrastructural studies showed the breakdown of syncytiotrophoblast integrity in regions associated with IEs (49).

These abnormal changes to the placenta were associated with decreased birth weight (45, 46, 49).

MiP and the subsequent immune activation are associated with placental pathologies that arise due to disruptions in placental tissue (trophoblast) and vascular development. An *in vitro* model demonstrated impaired trophoblast invasion and migration after incubation with sera from *P. falciparum*-infected women (50). In the same study, elevated levels of soluble factors that inhibit trophoblast invasion such as human chorionic gonadotropin and IL-10 were found in these sera. There was a corresponding decrease in the invasion stimulatory factors such as insulin-like growth factors and IL-8 (50). There are two main events in vascular development; vasculogenesis (formation of new blood vessels) and angiogenesis (development of blood vessels from existing vasculature). In a recent review, three main pathways that are associated with impaired vascular development and adverse birth outcomes in MiP were identified, including reduced bioavailability of L-arginine and nitric oxide, excessive complement activation and dysregulated hemoglobin-scavenging system due to increased intravascular haemolysis (51). In a Brazilian cohort, MiP altered the angiogenic profile of the placenta and was associated with increased placental barrier thickness, which is likely to affect nutrient and gas transfer (47). Often, *Plasmodium*-infected placentas become the foci of inflammation where maternal immune cells are recruited and retained. This concomitant inflammation generates various soluble inflammatory mediators including tumor necrosis factor- $\alpha$ , interferon- $\gamma$ , complement C5a, and C-reactive protein (33, 37). In addition, higher levels of chemoattractant proteins such as macrophage inflammatory protein-1 (alpha and beta) and monocyte chemoattractant protein-1 were observed (41, 52). These inflammatory mediators and chemoattractants are known to regulate the levels of key placental growth factors and receptors, including insulin-like growth factors, angiopoietin (1 and 2), soluble endoglin, sFlt-1 and VEGF (8, 37), which in turn disturb the delicate balance required for normal placental development. All of these analytes have been associated with reduced birth weight and LBW deliveries (33, 53). Taken together, placental trophoblast development, vascular development pathways and inflammatory responses appear to be interdependent and may synergistically contribute to poor birth outcomes in MiP. However, it remains to be determined if inflammatory inhibitors and/or promoters of placental growth factors may alleviate the impact of MiP on placental development and birth outcome.

### Intervillitis and Placental Insufficiency

Untreated *Plasmodium* infection during pregnancy increases the risk of intervillitis (inflammation in placental intervillous spaces). These spaces are occupied by maternal blood that surrounds the chorionic villi, serving as the materno-fetal exchange surface. Importantly, intervillitis, but not PM without intervillitis per se, was more commonly linked to adverse birth outcomes. This is particularly true in areas of high malaria transmission such as Tanzania and Malawi, where intervillitis was associated with abnormalities in the placenta and significantly higher rates of LBW (up to 50%)

(15, 54, 55). PM-associated intervillitis is characterized by the accumulation of mononuclear cells, predominantly monocytes/macrophages. The inflammatory foci serve as a physical barrier that may compromise placental transport function and cause hypoxia. These immune cells can also be activated to produce inflammatory molecules that affect various downstream signaling pathways in the placenta, leading to impairment of fetal growth.

Investigations on *Plasmodium*-infected placentas revealed that compromised nutrient transport is one of the molecular mechanisms contributing to growth restriction and reduced birth weight. In women with PM-associated intervillitis, reduced expression of glucose transporter isoform 1 (GLUT-1) on the syncytiotrophoblast basal membrane was reported (56). Transplacental glucose transport is primarily facilitated by GLUT-1 and its expression was positively correlated with birthweight. In addition, lower expression and activity of system A group of amino acid transporters were also found in PM-associated intervillitis. Maternal to cord blood ratios of several amino acids were lower in cases with intervillitis compared to uninfected controls and importantly, cord concentrations of amino acids were positively correlated with fetal/placental weight ratios (57). In a follow-up study, lower placental mammalian target of rapamycin (mTOR) activity was observed in infected placentas with intervillitis, which in turn is associated with reduced placental amino acid uptake and lower birthweight (58). Recently, increased placental autophagy was proposed as a possible mediator of placental insufficiency in PM and similarly, this has been reported in other non-infectious pregnancy complications such as preeclampsia and intrauterine growth restriction (59–61). The dysregulation of this process may negatively affect the uptake of amino acids by the placenta and future studies should further explore this association.

## PREVENTION OF MIP-ASSOCIATED LBW: A PROSPECTIVE ON CURRENT AND FUTURE STRATEGIES

### Insecticide-Treated Nets, Indoor Residual Spraying, and Intermittent Preventive Treatment


The World Health Organization recommends the prevention and management of MiP via the use insecticide-treated bed nets (ITN), IPTp and effective case management of malaria disease. Additionally, there are encouraging data to suggest that indoor residual spraying insecticide (IRS) may also be effective in reducing MiP and improving birth outcomes (62, 63). ITN and IRS, whether deployed individually or in combination, aim to reduce vector exposure and limit transmission, hence are likely to be beneficial (Figure 2). The use of ITN is a simple yet effective strategy to prevent *Plasmodium* infection and its consequences. There is substantial evidence from earlier studies suggesting that this strategy resulted in reduced prevalence of maternal parasitemia, improved birth weights and a 25% reduction in the risk of LBW deliveries (64–66). On the other hand, IRS, by decreasing vector contact, was associated with reduced risk of

preterm birth, LBW delivery and fetal/neonatal deaths in both HIV-negative and HIV-infected women (62, 63).

Currently, all pregnant women residing in areas with high malaria transmission are recommended to receive three or more treatment courses of IPTp with SP, where each course should be administered at least one month apart, starting in the second trimester (67). This replaces the original recommendation of two doses of SP, following substantial data that demonstrated reduced risk of preterm birth and LBW as well as improved birth weight when three or more courses were administered (68–70). In mathematical modeling studies, it was estimated that three or more doses of IPTp-SP uptake would lead to a 30% relative reduction in LBW occurrence (70–73).

Despite these preventive strategies, the prevalence of PM and LBW remain a huge threat to pregnancies in malarious regions due to several reasons. Given that IPTp is only administered from the second trimester onwards, pregnant women are not protected during the first trimester and the later weeks of third trimester. This inadequate IPTp coverage throughout pregnancy, poor population coverage, development of drug and insecticide resistance, and the use of suboptimal drugs which results in the failure to clear submicroscopic infection, are likely to contribute to increased risk of preterm birth, SGA and LBW (26, 74, 75). Following reports on the increased prevalence of SP-resistant parasites, there are concerns regarding the future effectiveness of this prophylactic regimen in protecting against consequences of MiP (72, 76, 77). For this reason, other antimalarial drugs such as amodiaquine, mefloquine, chloroquine–azithromycin and dihydroartemisinin-piperazine have been tested as potential alternatives to IPTp-SP (78, 79). Dihydroartemisinin-piperazine appears to be a promising choice, as trial results showed that malaria burden including maternal parasitemia and PM was significantly lower in women who received this drug compared to those who received SP (80, 81). However, dihydroartemisinin-piperazine did not lead to improved birth outcomes when compared with SP (81, 82). A recent systematic review showed that SP resistance decreased the effectiveness of IPTp especially in areas with high SP resistance, but this regimen is still associated with decreased cases of LBW (82).

The exact mechanisms by which SP leads to improved birth outcomes in the treated individuals remain elusive. In addition to malaria prevention, SP also serves as a broad-spectrum antibiotic that can resolve or prevent other infections of bacterial origin (sexually transmitted, reproductive tract and urinary tract infections) that have also been associated with adverse birth outcomes (69, 82). In addition, it was postulated that sulfadoxine can modulate bacterial microflora composition within the gut and vagina, which subsequently promotes weight gain (83). There is an ongoing study investigating the effect of SP on microbiota in the gut and/or vagina, in which the researchers proposed that higher birth weights following SP administration in pregnancy can be attributed to the modulation of these bacterial populations (84). To corroborate, antibiotic exposure during pregnancy led to increased gestational weight gain, which is an important predictor of birthweights (85). The overall reduction in malarial and other non-malarial infections during pregnancy is likely to



minimize chronic maternal inflammation, thus improving birth outcomes (9, 82).

Given the limitations associated with current drugs, there is an urgent need to evaluate the safety and efficacy of new antimalarials or a combination of preventive strategies that are suitable for wider coverage and at earlier time points in pregnancy to protect against MiP in the first trimester.

### Nutritional Interventions a Viable but Under-Interventions: Approach

Another major contributor to LBW is maternal undernutrition, a condition that is also highly prevalent in many areas with high malaria transmission. There is a growing number of studies suggesting that malaria and maternal undernutrition may worsen pregnancy outcomes (86, 87). Malnourishment during pregnancy, indicated by low body mass index and smaller mid-upper arm circumference, was associated with lower levels of antibodies to placental-binding IE and increased

parasite load in the placenta (88). The impaired development of protective antibodies may reduce the host's ability to clear infection, thus prolonged infection is likely to result in chronic inflammation in the placenta. In addition, undernutrition during pregnancy may also affect placental size and its functional capacity, given that maternal weight and gestational weight gain are both mediators of placental weight. All three factors were positively correlated to birthweight (89). Furthermore, both MiP and maternal undernourishment have been reported to impair trophoblast invasion and migration, as well as increase uterine artery resistance (50, 90, 91). In recent studies, MiP and undernourishment during pregnancy were observed to affect the levels of L-arginine-nitric oxide biogenesis; this pathway is essential for placental vascular development (29, 92).

In a comprehensive study that analyzed 23 systematic reviews on nutritional interventions during pregnancy, a few factors including provision of vitamin A, low-dose calcium, zinc and multiple micronutrients were shown to be associated with

reduced risk of LBW (93). Similarly, several earlier macronutrient supplementation studies in malarious regions such as Sub-Saharan Africa provided evidence of improved birthweight, increased gestational length and reduced odds of LBW (94). Using a MiP animal model, dietary L-arginine supplementation resulted in improved fetal weights, reduced levels of pro-inflammatory mediators and increased levels of angiogenic factors, the last of which were associated with improved placental vascular development and remodeling (29). Nutrient intervention appears to be a promising strategy to prevent LBW, hence more studies should be carried out to evaluate the effectiveness of different types of nutrient supplementation in reducing MiP-associated LBW. Distinguishing between the potential beneficial impacts of malaria prevention with IPTp and of nutrient supplementation will require careful study designs.

### Vaccines: the Pivotal Prevention Strategy

Efficacious malaria vaccines could potentially be one of the most effective strategies to prevent LBW in MiP. Previous studies have described the requirements of an effective vaccine for MiP, which include the ability to induce protective antibodies against placental-binding IEs to prevent their binding to CSA in the placenta *via* the parasites' VAR2CSA protein. These binding-inhibition antibodies have been associated with protection against preterm birth, increased gestational age, the delivery of heavier infants and importantly, reduced risk of LBW delivery (21). Furthermore, these binding-inhibition antibodies against whole parasites were demonstrated to be strain-independent, raising the possibility that targeting an immunogenically-conserved subunit or domain of VAR2CSA, which is a large (~350 kDa) multidomain protein, could be effective (95). Given its large size, later studies then identified a minimal binding region on the VAR2CSA protein that binds with high affinity to CSA. Antibodies in the sera collected from malaria-exposed pregnant women were able to bind to recombinant VAR2CSA and purified antibodies against this protein exhibited binding-inhibitory activity (96–99). Importantly, a study from Benin then demonstrated strong antibody responses against the VAR2CSA N-terminal region of DBL3X to be associated with protection against SGA and reduced prevalence of both LBW babies and placental infection at delivery, possibly by reducing parasite burden and thus lowering the risk of placental insufficiency (97). However, recent studies have identified distinct pathogenicity among the parasite variants and diversity in functional antibodies against different placental binding variants, suggesting that a polyvalent VAR2CSA-based vaccine may provide better protection (100, 101). To corroborate, two isoforms of VAR2CSA subunit protein that recently completed phase 1 clinical trial, ID1-ID2a (PAMVAC) and DBL1x-DBL2x (PRIMVAC), only demonstrated binding-inhibition activities against homologous parasite variants and the duration of immune responses is unknown (102, 103). Critically, the duration of immune responses and whether vaccination translates to clinical protection remains to be determined.

### FUTURE DIRECTIONS

Great advances have been made over the last two decades in understanding and reducing MiP, especially with effective anti-malarials and the use of ITNs during pregnancy. Despite this, our understanding of factors that contribute to LBW during MiP is still rather limited. In addition, with the increasing pressure of parasite resistance against existing drugs, alternatives such as a viable vaccine will be crucial to combat MiP. Hence, more research efforts should be channeled toward these areas of investigation. Herein, some areas of future research are proposed.

1. To better understand and manage the adverse birth consequences of MiP, there is a need to differentiate the relative contributions of SGA and preterm delivery to LBW. SGA and preterm delivery in MiP may be initiated by different molecular events, and hence may require different modes of interventions. In resource-limited malaria endemic areas where ultrasound is unavailable, pregnancy dating is based on recall of last menstrual period, abdominal palpation, or newborn assessments, all of which may be inaccurate. In addition, the reference curve for birth weights is based on those that have been established in the Western populations. Several studies have created population-specific charts detailing mean birth weights and percentiles at different gestational ages to have a better representation of their own populations (10, 104). In addition, a global healthcare project has developed standards and tools for assessing newborn weight, length and head circumference by gestational age and sex (105). These can lead to more accurate classifications of birth outcomes in MiP and studies on their effectiveness in differentiating SGA and preterm birth can be done.
2. Changes to the placenta in PM are only studied upon delivery, given the invasive nature of sampling placental blood or biopsies during pregnancy. However, this rarely captures the whole picture of placental events that occurred throughout pregnancy, limiting our interpretation of how placental changes during gestation can lead to LBW. Although the use of animal models may address this challenge, there are concerns regarding the relevance and transferability of the findings to human disease (106). One way to better understand the placental pathophysiology during MiP is to employ the use of Doppler ultrasound to investigate utero- and fetoplacental blood flow and resistance. In earlier studies, MiP in the first half of gestation was associated with altered uteroplacental blood flow, suggesting the possibility of vascular deficiency (90, 107). This technique, together with measurement of various maternal analytes in the peripheral blood, may provide a clearer picture of the events in the placenta during MiP.
3. Our current understanding on inflammation in PM focuses on the roles of monocytes and macrophages as the main contributors of inflammatory mediators associated with LBW. However, there are recent studies suggesting that neutrophils, which are the most abundant leukocytes in the peripheral blood, may also play a role in orchestrating the inflammation (108, 109). Their role in MiP requires further clarification.

4. Our current understanding of protective antibodies in MiP is that these antibodies should be able to inhibit IEs binding to the placenta and promote opsonic phagocytosis (21). However, their importance and relative contribution to protection through other immune effector mechanisms such as antibody-dependent respiratory burst and antibody-dependent cellular cytotoxicity are less well-understood. This knowledge will be important in vaccine design and the evaluation of vaccine efficacy.
5. Early studies in The Gambia and Nigeria demonstrated that passive transfer of anti-malarial antibodies resolved malaria (110, 111). Currently, there are existing clinical trials that are investigating the protective efficacy of monoclonal antibodies as anti-infective agents (ClinicalTrials.gov Identifier: NCT04327310 and NCT04206332). Therefore, monoclonal antibodies, targeting either the domains of VAR2CSA or the circumsporozoite protein to prevent establishment of infection can be further developed as therapeutics for MiP.
6. In terms of improving vaccine design, there is a need to identify conserved subdomains of VAR2CSA that can induce protective antibodies, against the different parasite variants.
7. SP may be less efficacious in areas with high SP-resistant parasites. Moreover, SP is only given at the start of second trimester, but there is substantial evidence showing that infection during the first trimester can also greatly impact birth outcomes (24, 26). Hence new antimalarial drug combinations that can be administered in the first trimester need to be evaluated in future clinical trials.
8. SP, a broad-spectrum antibiotic, may be effective against sexually transmitted and reproductive tract infections (highly prevalent in malaria endemic regions), thus it may resolve infections other than malaria to improve adverse birth outcomes (69). Future studies to explore the use of effective antimalarials coupled with SP may be beneficial.
9. Malnutrition is an important contributor to LBW, and nutrient supplementations during pregnancy appear to be an attractive and feasible intervention to minimize the risk of LBW deliveries. However, the beneficial effect of nutrient supplementation may be masked if administered together with

IPTp, thus undermining its impact on birth outcomes. Hence, future trials of nutrient supplementations require careful study designs such as having intermittent-screening and treatment with nutrient supplementations, or choosing a trial site in a lower transmission setting where IPTp is not a first line policy.

## CONCLUSION

As of 2019, 38 countries and territories were granted the “malaria-free” status by WHO, while transmission continues in other regions. Hence, pregnant women remain at risk of MiP, which leads to increased mortality and morbidity in both the mother and her infant. MiP-associated LBW is preventable, but there needs to be a concerted effort in the adoption and implementation of current prevention strategies in malarious areas. Continuous efforts in research are needed, to better understand the molecular mechanisms associated with poor birth outcomes, and ultimately to enable design of specific targeted approaches for improving birth outcomes. In the face of increased parasite resistance, the effectiveness of IPT with SP in preventing this health burden may be at threat in the near future. Therefore, there is an urgent need to design and evaluate other therapeutic options that can be used to protect against MiP and its deleterious consequences.

## AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

## FUNDING

CC received support from Ministry of Education (MOE) Fundamental Research Grant Scheme of Malaysia: ID FRGS/1/2015/SKK08/Taylor/03/2. SR and WH were supported by grants from the National Health and Medical Research Council of Australia (GNT1143946; GNT1092789). AT was supported by Nanyang Technological University Research Scholarship Block Fellowship of Singapore and Nanyang Technological University Singapore Start-up grant.

## REFERENCES

1. World Health Organization. *World Malaria Report 2019*. Geneva: World Health Organization (2019).
2. Salanti A, Staalsoe T, Lavstsen T, Jensen ATR, Sowa MPK, Arnot DE, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering *Plasmodium falciparum* involved in pregnancy-associated malaria. *Mol Microbiol*. (2003) 49:179–91. doi: 10.1046/j.1365-2958.2003.03570.x
3. Veenstra van Nieuwenhoven AL, Heineman MJ, Faas MM. The immunology of successful pregnancy. *Hum Reprod Update*. (2003) 9:347–57. doi: 10.1093/humupd/dmg026
4. World Health Organization. *Low Birthweight: Country, Regional and Global Estimates*. Geneva: World Health Organization (2004).
5. Sykes L, MacIntyre DA, Yap XJ, Teoh TG, Bennett PR. The Th1:th2 dichotomy of pregnancy and preterm labour. *Mediators Inflamm*. (2012) 2012:967629. doi: 10.1155/2012/967629
6. McDonald CR, Weckman AM, Conroy AL, Olwoch P, Natureeba P, Kanya MR, et al. Systemic inflammation is associated with malaria and preterm birth in women living with HIV on antiretrovirals and co-trimoxazole. *Sci Rep*. (2019) 9:6758. doi: 10.1038/s41598-019-43191-w
7. Nkwabong E, Mayane DN, Meka E, Essiben F. Malaria in the third trimester and maternal-perinatal outcome. *Int J Gynaecol Obstet*. (2020) 8:13261. doi: 10.1002/ijgo.13261
8. Umbers AJ, Boeuf P, Clapham C, Stanicic DI, Baiwog F, Mueller I, et al. Placental malaria-associated inflammation disturbs the insulin-like growth factor axis of fetal growth regulation. *J Infect Dis*. (2011) 203:561–9. doi: 10.1093/infdis/jiq080
9. Unger HW, Hansa AP, Buffet C, Hasang W, Teo A, Randall L, et al. Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection. *Sci Rep*. (2019) 9:2260. doi: 10.1038/s41598-019-38821-2



10. Rijken MJ, De Livera AM, Lee SJ, Boel ME, Rungwilaekhirin S, Wiladphaingern J, et al. Quantifying low birth weight, preterm birth and small-for-gestational-age effects of malaria in pregnancy: a population cohort study. *PLoS ONE*. (2014) 9:e100247. doi: 10.1371/journal.pone.0100247
11. Desai M, ter Kuile FO, Nosten F, McGready R, Asamo K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. *Lancet Infect Dis*. (2007) 7:93–104. doi: 10.1016/S1473-3099(07)70021-X
12. Upadhyay RP, Naik G, Choudhary TS, Chowdhury R, Taneja S, Bhandari N, et al. Cognitive and motor outcomes in children born low birth weight: a systematic review and meta-analysis of studies from South Asia. *BMC Pediatr*. (2019) 19:35. doi: 10.1186/s12887-019-1408-8
13. Knop MR, Geng TT, Gorny AW, Ding R, Li C, Ley SH, et al. Birth weight and risk of type 2 diabetes mellitus, cardiovascular disease, and hypertension in adults: a meta-analysis of 7 646 267 participants from 135 studies. *J Am Heart Assoc*. (2018) 7:e008870. doi: 10.1161/JAHA.118.008870
14. Rogerson SJ, Mkundika P, Kanjala MK. Diagnosis of *Plasmodium falciparum* malaria at delivery: comparison of blood film preparation methods and of blood films with histology. *J Clin Microbiol*. (2003) 41:1370–4. doi: 10.1128/JCM.41.4.1370-1374.2003
15. Muehlenbachs A, Fried M, McGready R, Harrington WE, Mutabingwa TK, Nosten F, et al. A novel histological grading scheme for placental malaria applied in areas of high and low malaria transmission. *J Infect Dis*. (2010) 202:1608–16. doi: 10.1086/656723
16. Rogerson SJ, Chaiyaroj SC, Ng K, Reeder JC, Brown GV. Chondroitin sulfate A is a cell surface receptor for *Plasmodium falciparum*-infected erythrocytes. *J Exp Med*. (1995) 182:15–20. doi: 10.1084/jem.182.1.15
17. Tuikue Ndam NG, Salanti A, Bertin G, Dahlbäck M, Fievet N, Turner L, et al. High level of var2csa transcription by *Plasmodium falciparum* isolated from the placenta. *J Infect Dis*. (2005) 192:331–5. doi: 10.1086/430933
18. Yosaatmadja F, Andrews KT, Duffy MF, Brown GV, Beeson JG, Rogerson SJ. Characterization of VAR2CSA-deficient *Plasmodium falciparum*-infected erythrocytes selected for adhesion to the BeWo placental cell line. *Malar J*. (2008) 7:51. doi: 10.1186/1475-2875-7-51
19. Dorin-Semblat D, Tétard M, Claës A, Semblat JP, Dechavanne S, Fourati Z, et al. Phosphorylation of the VAR2CSA extracellular region is associated with enhanced adhesive properties to the placental receptor CSA. *PLoS Biol*. (2019) 17:e3000308. doi: 10.1371/journal.pbio.3000308
20. Fodjo BA, Atemnkeng N, Esemu L, Yuosembom EK, Quakyi IA, Tchinda VH, et al. Antibody responses to the full-length VAR2CSA and its DBL domains in Cameroonian children and teenagers. *Malar J*. (2016) 15:532. doi: 10.1186/s12936-016-1585-y
21. Teo A, Feng G, Brown GV, Beeson JG, Rogerson SJ. Functional antibodies and protection against blood-stage malaria. *Trends Parasitol*. (2016) 32:887–98. doi: 10.1016/j.pt.2016.07.003
22. Cutts JC, Agius PA, Zaw L, Powell R, Moore K, Draper B, et al. Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review. *BMC Med*. (2020) 18:14. doi: 10.1186/s12916-019-1467-6
23. Agbota G, Accrombessi M, Cottrell G, Martin-Prével Y, Milet J, Ouédraogo S, et al. Increased risk of malaria during the first year of life in small-for-gestational-age infants: a longitudinal study in Benin. *J Infect Dis*. (2018) 219:1642–51. doi: 10.1093/infdis/jiy699
24. Moore KA, Simpson JA, Wiladphaingern J, Min AM, Pimanpanarak M, Paw MK, et al. Influence of the number and timing of malaria episodes during pregnancy on prematurity and small-for-gestational-age in an area of low transmission. *BMC Med*. (2017) 15:117. doi: 10.1186/s12916-017-0877-6
25. Kalilani-Phiri L, Thesing PC, Nyirenda OM, Mawindo P, Madanitsa M, Membe G, et al. Timing of malaria infection during pregnancy has characteristic maternal, infant and placental outcomes. *PLoS ONE*. (2013) 8:e74643. doi: 10.1371/journal.pone.0074643
26. Elphinstone RE, Weckman AM, McDonald CR, Tran V, Zhong K, Madanitsa M, et al. Early malaria infection, dysregulation of angiogenesis, metabolism and inflammation across pregnancy, and risk of preterm birth in Malawi: a cohort study. *PLoS Med*. (2019) 16:e1002914. doi: 10.1371/journal.pmed.1002914
27. Ategeka J, Kakuru A, Kajubi R, Wasswa R, Ochokoru H, Arinaitwe E, et al. Relationships between measures of malaria at delivery and adverse birth outcomes in a high-transmission area of Uganda. *J Infect Dis*. (2020) 222:863–70. doi: 10.1093/infdis/jiaa156
28. Karumanchi SA, Haig D. Flt1, pregnancy, and malaria: evolution of a complex interaction. *Proc Natl Acad Sci USA*. (2008) 105:14243–4. doi: 10.1073/pnas.0807932105
29. McDonald CR, Cahill LS, Gamble JL, Elphinstone R, Gazdzinski LM, Zhong KJY, et al. Malaria in pregnancy alters l-arginine bioavailability and placental vascular development. *Sci Transl Med*. (2018) 10:eaan6007. doi: 10.1126/scitranslmed.aan6007
30. Krause BJ, Hanson MA, Casanello P. Role of nitric oxide in placental vascular development and function. *Placenta*. (2011) 32:797–805. doi: 10.1016/j.placenta.2011.06.025
31. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. *Lancet*. (2008) 371:261–9. doi: 10.1016/S0140-6736(08)60136-1
32. Brydges CR, Landes JK, Reid CL, Campbell C, French N, Anderson M. Cognitive outcomes in children and adolescents born very preterm: a meta-analysis. *Dev Med Child Neurol*. (2018) 60:452–68. doi: 10.1111/dmcn.13685
33. Fried M, Kurtis JD, Swihart B, Pond-Tor S, Barry A, Sidibe Y, et al. Systemic inflammatory response to malaria during pregnancy is associated with pregnancy loss and preterm delivery. *Clin Infect Dis*. (2017) 65:1729–35. doi: 10.1093/cid/cix623
34. Brabin B, Gies S, Roberts SA, Diallo S, Lompo OM, Kazienga A, et al. Excess risk of preterm birth with periconceptional iron supplementation in a malaria endemic area: analysis of secondary data on birth outcomes in a double blind randomized controlled safety trial in Burkina Faso. *Malar J*. (2019) 18:161. doi: 10.1186/s12936-019-2797-8
35. Mikomangwa WP, Oms M, Aklillu E, Kamuhabwa AAR. Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region. *BMC Pregnancy Childbirth*. (2019) 19:236. doi: 10.1186/s12884-019-2397-1
36. Rahmati S, Azami M, Badfar G, Parizad N, Sayehmiri K. The relationship between maternal anemia during pregnancy with preterm birth: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med*. (2020) 33:2679–89. doi: 10.1080/14767058.2018.1555811
37. Conroy AL, Silver KL, Zhong K, Rennie M, Ward P, Sarma JV, et al. Complement activation and the resulting placental vascular insufficiency drives fetal growth restriction associated with placental malaria. *Cell Host Microbe*. (2013) 13:215–26. doi: 10.1016/j.chom.2013.01.010
38. Mahamat O, Gisele Nduum K, Laurentine S, Ngum Helen N. Cord malaria infection, complement activation, oxidative stress, gestational age, and birth weight, characterized by high *Plasmodium falciparum* prevalence in Bamenda, Cameroon. *J Trop Med*. (2020) 2020:7209542. doi: 10.1155/2020/7209542
39. Mansor SM, Molyneux ME, Taylor TE, Ward SA, Wirima JJ, Edwards G. Effect of *Plasmodium falciparum* malaria infection on the plasma concentration of alpha 1-acid glycoprotein and the binding of quinine in Malawian children. *Br J Clin Pharmacol*. (1991) 32:317–21. doi: 10.1111/j.1365-2125.1991.tb03905.x
40. Silamut K, Molunto P, Ho M, Davis TM, White NJ. Alpha 1-acid glycoprotein (orosomuroid) and plasma protein binding of quinine in falciparum malaria. *Br J Clin Pharmacol*. (1991) 32:311–5. doi: 10.1111/j.1365-2125.1991.tb03904.x
41. Abrams ET, Brown H, Chensue SW, Turner GDH, Tadesse E, Lema VM, et al. Host response to malaria during pregnancy: placental monocyte recruitment is associated with elevated  $\beta$  chemokine expression. *J Immunol*. (2003) 170:2759–64. doi: 10.4049/jimmunol.170.5.2759
42. Fontes KN, Reginatto MW, Silva NL, Andrade CBV, Bloise FF, Monteiro VRS, et al. Dysregulation of placental ABC transporters in a murine model of malaria-induced preterm labor. *Sci Rep*. (2019) 9:11488. doi: 10.1038/s41598-019-47865-3
43. Tuikue Ndam N, Tornyigah B, Dossou AY, Escriou G, Nielsen MA, Salanti A, et al. Persistent *Plasmodium falciparum* infection in women with an intent to become pregnant as a risk factor for pregnancy-associated malaria. *Clin Infect Dis*. (2018) 67:1890–6. doi: 10.1093/cid/ciy380
44. Hounkonnou CPA, Briand V, Fievet N, Accrombessi M, Yovo E, Mama A, et al. Dynamics of submicroscopic *Plasmodium falciparum* infections throughout pregnancy: a preconception cohort study in Benin. *Clin Infect Dis*. (2019) 71:166–74. doi: 10.1093/cid/ciz748
45. Moeller SL, Nyengaard JR, Larsen LG, Nielsen K, Bygbjerg IC, Msemu OA, et al. Malaria in early pregnancy and the development of the

- placental vasculature. *J Infect Dis.* (2019) 220:1425–34. doi: 10.1093/infdis/jiy735
46. Crocker IP, Tanner OM, Myers JE, Bulmer JN, Walraven G, Baker PN. Syncytiotrophoblast degradation and the pathophysiology of the malaria-infected placenta. *Placenta.* (2004) 25:273–82. doi: 10.1016/j.placenta.2003.09.010
  47. Ataíde R, Murillo O, Dombrowski JG, Souza RM, Lima FA, Lima GF, et al. Malaria in pregnancy interacts with and alters the angiogenic profiles of the placenta. *PLoS Negl Trop Dis.* (2015) 9:e0003824. doi: 10.1371/journal.pntd.0003824
  48. Ahenkorah J, Tetteh-Quarcoo PB, Nuamah MA, Kwansa-Bentum B, Nuamah HG, Hottor B, et al. The impact of *Plasmodium* infection on placental histomorphology: a stereological preliminary study. *Infect Dis Obstet Gynecol.* (2019) 2019:2094560. doi: 10.1155/2019/2094560
  49. Kidima WB. Syncytiotrophoblast functions and fetal growth restriction during placental malaria: updates and implication for future interventions. *Biomed Res Int.* (2015) 2015:451735. doi: 10.1155/2015/451735
  50. Umbers AJ, Stanisic DI, Ome M, Wangnapi R, Hanieh S, Unger HW, et al. Does malaria affect placental development? Evidence from in vitro models. *PLoS ONE.* (2013) 8:e55269. doi: 10.1371/annotation/4faa7351-837e-4531-a513-0ea80277017f
  51. Ngai M, Weckman AM, Erice C, McDonald CR, Cahill LS, Sled JG, et al. Malaria in pregnancy and adverse birth outcomes: new mechanisms and therapeutic opportunities. *Trends Parasitol.* (2020) 36:127–37. doi: 10.1016/j.pt.2019.12.005
  52. Sampaio NG, Eriksson EM, Schofield L. *Plasmodium falciparum* PfEMP1 modulates monocyte/macrophage transcription factor activation and cytokine and chemokine responses. *Infect Immun.* (2018) 86:00447–17. doi: 10.1128/IAI.00447-17
  53. Silver KL, Zhong K, Leke RGF, Taylor DW, Kain KC. Dysregulation of angiopoietins is associated with placental malaria and low birth weight. *PLoS ONE.* (2010) 5:e9481. doi: 10.1371/journal.pone.0009481
  54. Ordi J, Ismail MR, Ventura PJ, Kahigwa E, Hirt R, Cardesa A, et al. Massive chronic intervillitis of the placenta associated with malaria infection. *Am J Surg Pathol.* (1998) 22:1006–11. doi: 10.1097/0000478-199808000-00011
  55. Rogerson SJ, Pollina E, Getachew A, Tadesse E, Lema VM, Molyneux ME. Placental monocyte infiltrates in response to *Plasmodium falciparum* malaria infection and their association with adverse pregnancy outcomes. *Am J Trop Med Hyg.* (2003) 68:115–9. doi: 10.4269/ajtmh.2003.68.1.0680115
  56. Chandrasiri UP, Chua CL, Umbers AJ, Chaluluka E, Glazier JD, Rogerson SJ, et al. Insight into the pathogenesis of fetal growth restriction in placental malaria: decreased placental glucose transporter isoform 1 expression. *J Infect Dis.* (2014) 209:1663–7. doi: 10.1093/infdis/jit803
  57. Boeuf P, Aitken EH, Chandrasiri U, Chua CL, McInerney B, McQuade L, et al. *Plasmodium falciparum* malaria elicits inflammatory responses that dysregulate placental amino acid transport. *PLoS Pathog.* (2013) 9:e1003153. doi: 10.1371/journal.ppat.1003153
  58. Dimasuay KG, Aitken EH, Rosario F, Njie M, Glazier J, Rogerson SJ, et al. Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight. *BMC Med.* (2017) 15:1. doi: 10.1186/s12916-016-0759-3
  59. Dimasuay KG, Gong L, Rosario F, McBryde E, Spelman T, Glazier J, et al. Impaired placental autophagy in placental malaria. *PLoS ONE.* (2017) 12:e0187291. doi: 10.1371/journal.pone.0187291
  60. Lima FA, Barateiro A, Dombrowski JG, de Souza RM, Costa DS, Murillo O, et al. *Plasmodium falciparum* infection dysregulates placental autophagy. *PLoS ONE.* (2019) 14:e0226117. doi: 10.1371/journal.pone.0226117
  61. Nakashima A, Tsuda S, Kusabiraki T, Aoki A, Ushijima A, Shima T, et al. Current understanding of autophagy in pregnancy. *Int J Mol Sci.* (2019) 20:2342. doi: 10.3390/ijms20092342
  62. Muhindo MK, Kakuru A, Natureeba P, Awori P, Olwoch P, Ategeka J, et al. Reductions in malaria in pregnancy and adverse birth outcomes following indoor residual spraying of insecticide in Uganda. *Malar J.* (2016) 15:437. doi: 10.1186/s12936-016-1489-x
  63. Roh ME, Shiboski S, Natureeba P, Kakuru A, Muhindo M, Ochieng T, et al. Protective effect of indoor residual spraying of insecticide on preterm birth among pregnant women with HIV infection in Uganda: a secondary data analysis. *J Infect Dis.* (2017) 216:1541–9. doi: 10.1093/infdis/jix533
  64. Gamble C, Ekwari JP, ter Kuile FO. Insecticide-treated nets for preventing malaria in pregnancy. *Cochrane Database Syst Rev.* (2006) 19:CD003755. doi: 10.1002/14651858.CD003755.pub2
  65. Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ. Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets. *PLoS ONE.* (2010) 5:e12012. doi: 10.1371/journal.pone.0012012
  66. Eisele TP, Larsen DA, Anglewicz PA, Keating J, Yukich J, Bennett A, et al. Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. *Lancet Infect Dis.* (2012) 12:942–9. doi: 10.1016/S1473-3099(12)70222-0
  67. World Health Organization. *WHO Policy Brief for the Implementation of Intermittent Preventive Treatment of Malaria in Pregnancy Using Sulfadoxine-Pyrimethamine (IPTp-SP).* Geneva: World Health Organization (2013).
  68. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. *JAMA.* (2013) 309:594–604. doi: 10.1001/jama.2012.216231
  69. Chico RM, Chaponda EB, Ariti C, Chandramohan D. Sulfadoxine-pyrimethamine exhibits dose-response protection against adverse birth outcomes related to malaria and sexually transmitted and reproductive tract infections. *Clin Infect Dis.* (2017) 64:1043–51. doi: 10.1093/cid/cix026
  70. Quakyi I, Torniyigah B, Houze P, Kusi KA, Coleman N, Escriou G, et al. High uptake of intermittent preventive treatment of malaria in pregnancy is associated with improved birth weight among pregnant women in Ghana. *Sci Rep.* (2019) 9:19034. doi: 10.1038/s41598-019-55046-5
  71. Cates JE, Westreich D, Unger HW, Bauserman M, Adair L, Cole SR, et al. Intermittent preventive therapy in pregnancy and incidence of low birth weight in malaria-endemic countries. *Am J Public Health.* (2018) 108:399–406. doi: 10.2105/AJPH.2017.304251
  72. van Eijk AM, Larsen DA, Kayentao K, Koshy G, Slaughter DEC, Roper C, et al. Effect of *Plasmodium falciparum* sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. *Lancet Infect Dis.* (2019) 19:546–56. doi: 10.1016/S1473-3099(18)30732-1
  73. Mlugu EM, Minzi O, Asghar M, Färner A, Kamuhabwa AAR, Aklillu E. Effectiveness of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria and adverse birth outcomes in pregnant women. *Pathogens.* (2020) 9:207. doi: 10.3390/pathogens9030207
  74. Cottrell G, Moussiliou A, Luty AJ, Cot M, Fievet N, Massougbdji A, et al. Submicroscopic *Plasmodium falciparum* infections are associated with maternal anemia, premature births, and low birth weight. *Clin Infect Dis.* (2015) 60:1481–8. doi: 10.1093/cid/civ122
  75. Hounkonnou CPA, Ndam NT, Fievet N, Accrombessi M, Yovo E, Mama A, et al. Sub-optimal intermittent preventive treatment in pregnancy (IPTp) is associated with an increased risk of submicroscopic *P. falciparum* infection in pregnant women: a prospective cohort study in Benin. *Clin Infect Dis.* (2020) 9:ciaa1355. doi: 10.1093/cid/ciaa1355
  76. Fagbemi KA, Adebuseyi SA, Nderu D, Adedokun SA, Pallerla SR, Amoo AJO, et al. Analysis of sulphadoxine-pyrimethamine resistance-associated mutations in *Plasmodium falciparum* isolates obtained from asymptomatic pregnant women in Ogun State, Southwest Nigeria. *Infect Genet Evol.* (2020) 85:104503. doi: 10.1016/j.meegid.2020.104503
  77. Taylor SM, Levitt B, Freedman B, Madanitsa M, Thwai KL, Kalilani-Phiri L, et al. Interactions between antenatal sulfadoxine-pyrimethamine, drug-resistant *Plasmodium falciparum* parasites, and delivery outcomes in Malawi. *J Infect Dis.* (2020) 222:661–9. doi: 10.1093/infdis/jiaa145
  78. Kimani J, Phiri K, Kamiza S, Duparc S, Ayoub A, Rojo R, et al. Efficacy and safety of azithromycin-chloroquine versus sulfadoxine-pyrimethamine for intermittent preventive treatment of *Plasmodium falciparum* malaria infection in pregnant women in Africa: an open-label, randomized trial. *PLoS ONE.* (2016) 11:e0157045. doi: 10.1371/journal.pone.0157045
  79. González R, Pons-Duran C, Piqueras M, Aponte JJ, Ter Kuile FO, Menéndez C. Mefloquine for preventing malaria in pregnant women. *Cochrane Database Syst Rev.* (2018) 3:CD011444. doi: 10.1002/14651858.CD011444.pub3

80. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, et al. Dihydroartemisinin-piperazine for the prevention of malaria in pregnancy. *N Engl J Med*. (2016) 374:928–39. doi: 10.1056/NEJMoa1509150
81. Kajubi R, Ochieng T, Kakuru A, Jagannathan P, Nakalembe M, Ruel T, et al. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperazine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. *Lancet*. (2019) 393:1428–39. doi: 10.1016/S0140-6736(18)32224-4
82. Roh ME, Ter Kuile FO, Rerolle F, Glymour MM, Shiboski S, Gosling R, et al. Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis. *Lancet Glob Health*. (2020) 8:e942–53. doi: 10.1016/S2214-109X(20)30119-4
83. Gutman J, Slutsker L. Intermittent preventive treatment with sulfadoxine-pyrimethamine: more than just an antimalarial? *Am J Trop Med Hyg*. (2017) 96:9–10. doi: 10.4269/ajtmh.16-0888
84. Meshnick SR, Carroll IM. *Sulfadoxine-Pyrimethamine IPTp in Malawi: Effects on the Gut and Vaginal Microbiomes*. (2016). Available online at: <https://grantome.com/grant/NIH/R21-AI125800-02> (accessed February 2, 2021).
85. Unger HW, Wangnapi RA, Ome-Kaius M, Boeuf P, Karl S, Mueller I, et al. Azithromycin-containing intermittent preventive treatment in pregnancy affects gestational weight gain, an important predictor of birthweight in Papua New Guinea - an exploratory analysis. *Matern Child Nutr*. (2016) 12:699–712. doi: 10.1111/mcn.12215
86. Lovel HJ, Newby RM, Hillier VF. Severe placental malaria and maternal shortness, thinness, and small skeletal size in rural Congo: cohort study. *BMJ*. (2005) 331:1439–40. doi: 10.1136/bmj.331.7530.1439
87. Cates JE, Unger HW, Briand V, Fievet N, Valea I, Tinto H, et al. Malaria, malnutrition, and birthweight: a meta-analysis using individual participant data. *PLoS Med*. (2017) 14:e1002373. doi: 10.1371/journal.pmed.1002373
88. Chandrasiri UP, Fowkes FJ, Richards JS, Langer C, Fan YM, Taylor SM, et al. The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial. *Malar J*. (2015) 14:193. doi: 10.1186/s12936-015-0707-2
89. Ashorn P, Hallamaa L, Allen LH, Ashorn U, Chandrasiri U, Deitchler M, et al. Co-causation of reduced newborn size by maternal undernutrition, infections, and inflammation. *Matern Child Nutr*. (2018) 14:e12585. doi: 10.1111/mcn.12585
90. Griffin JB, Lokomba V, Landis SH, Thorp JM Jr, Herring AH, Tshetu AK, et al. Plasmodium falciparum parasitaemia in the first half of pregnancy, uterine and umbilical artery blood flow, and foetal growth: a longitudinal Doppler ultrasound study. *Malar J*. (2012) 11:319. doi: 10.1186/1475-2875-11-319
91. Baker BC, Hayes DJ, Jones RL. Effects of micronutrients on placental function: evidence from clinical studies to animal models. *Reproduction*. (2018) 156:R69–82. doi: 10.1530/REP-18-0130
92. Weckman AM, McDonald CR, Baxter JB, Fawzi WW, Conroy AL, Kain KC. Perspective: L-arginine and L-citrulline supplementation in pregnancy: a potential strategy to improve birth outcomes in low-resource settings. *Adv Nutr*. (2019) 10:765–77. doi: 10.1093/advances/nmz015
93. da Silva Lopes K, Ota E, Shakya P, Dagvadorj A, Balogun OO, Peña-Rosas JP, et al. Effects of nutrition interventions during pregnancy on low birth weight: an overview of systematic reviews. *BMJ Glob Health*. (2017) 2:e000389. doi: 10.1136/bmjgh-2017-000389
94. Unger HW, Ashorn P, Cates JE, Dewey KG, Rogerson SJ. Undernutrition and malaria in pregnancy - a dangerous dyad? *BMC Med*. (2016) 14:142. doi: 10.1186/s12916-016-0695-2
95. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies block malaria. *Nature*. (1998) 395:851–2. doi: 10.1038/27570
96. Clausen TM, Christoffersen S, Dahlback M, Langkilde AE, Jensen KE, Resende M, et al. Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria. *J Biol Chem*. (2012) 287:23332–45. doi: 10.1074/jbc.M112.348839
97. Ndam NT, Denoed-Ndam L, Doritchamou J, Viwami F, Salanti A, Nielsen MA, et al. Protective antibodies against placental malaria and poor outcomes during pregnancy. *Benin. Emerg Infect Dis*. (2015) 21:813–23. doi: 10.3201/eid2105.141626
98. Doritchamou JY, Herrera R, Aebig JA, Morrison R, Nguyen V, Reiter K, et al. VAR2CSA domain-specific analysis of naturally acquired functional antibodies to Plasmodium falciparum placental malaria. *J Infect Dis*. (2016) 214:577–86. doi: 10.1093/infdis/jiw197
99. Chêne A, Gangnard S, Dechavanne C, Dechavanne S, Srivastava A, Tétard M, et al. Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development. *NPJ Vaccines*. (2018) 3:28. doi: 10.1038/s41541-018-0064-6
100. Patel JC, Hathaway NJ, Parobek CM, Thwai KL, Madanitsa M, Khairallah C, et al. Increased risk of low birth weight in women with placental malaria associated with P. falciparum VAR2CSA clade. *Sci Rep*. (2017) 7:7768. doi: 10.1038/s41598-017-04737-y
101. Doritchamou J, Teo A, Morrison R, Arora G, Kwan J, Manzella-Lapeira J, et al. Functional antibodies against placental malaria parasites are variant dependent and differ by geographic region. *Infect Immun*. (2019) 87:00865–18. doi: 10.1128/IAI.00865-18
102. Mordmüller B, Sulyok M, Egger-Adam D, Resende M, de Jongh WA, Jensen MH, et al. First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, A vaccine candidate to prevent pregnancy-associated malaria. *Clin Infect Dis*. (2019) 69:1509–16. doi: 10.1093/cid/ciy1140
103. Sirima SB, Richert L, Chêne A, Konate AT, Campion C, Dechavanne S, et al. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomized, double-blind, placebo-controlled study. *Lancet Infect Dis*. (2020) 20:585–97. doi: 10.1016/S1473-3099(19)30739-X
104. Kemfeng Ngowa JD, Domkam I, Ngassam A, Nguefack-Tsague G, Dobgima Pisho W, Noa C, et al. References of birth weights for gestational age and sex from a large cohort of singleton births in cameroon. *Obstet Gynecol Int*. (2014) 2014:361451. doi: 10.1155/2014/361451
105. Villar J, Cheikh Ismail L, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the newborn cross-sectional study of the INTERGROWTH-21st project. *Lancet*. (2014) 384:857–68. doi: 10.1016/S0140-6736(14)60932-6
106. Doritchamou J, Teo A, Fried M, Duffy PE. Malaria in pregnancy: the relevance of animal models for vaccine development. *Lab Anim*. (2017) 46:388–98. doi: 10.1038/lablan.1349
107. Ome-Kaius M, Karl S, Wangnapi RA, Bolnga JW, Mola G, Walker J, et al. Effects of Plasmodium falciparum infection on umbilical artery resistance and intrafetal blood flow distribution: a Doppler ultrasound study from Papua New Guinea. *Malar J*. (2017) 16:35. doi: 10.1186/s12936-017-1689-z
108. Chua CLL, Robinson LJ, Baiwog F, Stanisc DI, Hamilton JA, Brown GV, et al. High numbers of circulating pigmented polymorphonuclear neutrophils as a prognostic marker for decreased birth weight during malaria in pregnancy. *Int J Parasitol*. (2015) 45:107–11. doi: 10.1016/j.ijpara.2014.12.002
109. Aitken EH, Alemu A, Rogerson SJ. Neutrophils and malaria. *Front Immunol*. (2018) 9:3005. doi: 10.3389/fimmu.2018.03005
110. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. *Nature*. (1961) 192:733–7. doi: 10.1038/192733a0
111. Edozien JC, Gilles HM, Udeozo IOK. Adult and cord-blood gamma-globulin and immunity to malaria in Nigerians. *Lancet*. (1962) 280:951–5. doi: 10.1016/S0140-6736(62)90725-0

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor declared a past co-authorship with one of the authors SR.

Copyright © 2021 Chua, Hasang, Rogerson and Teo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.



Minerva Access is the Institutional Repository of The University of Melbourne

**Author/s:**

Chua, CLL; Hasang, W; Rogerson, SJ; Teo, A

**Title:**

Poor Birth Outcomes in Malaria in Pregnancy: Recent Insights Into Mechanisms and Prevention Approaches

**Date:**

2021-03-15

**Citation:**

Chua, C. L. L., Hasang, W., Rogerson, S. J. & Teo, A. (2021). Poor Birth Outcomes in Malaria in Pregnancy: Recent Insights Into Mechanisms and Prevention Approaches. FRONTIERS IN IMMUNOLOGY, 12, <https://doi.org/10.3389/fimmu.2021.621382>.

**Persistent Link:**

<http://hdl.handle.net/11343/273318>

**File Description:**

Published version

**License:**

CC BY